Aptose Biosciences Inc.
No enriched coverage for $APTOF in the last 7 days.
No SEC Form 4 filings for $APTOF in the last 30 days.
SAN DIEGO and TORONTO, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) ( TSX:APS, OTC:APTOF ) and Hanmi Pharmaceutical Co. Ltd. ( "Hanmi" ) today announced that Aptose, Hanmi and HS North America Ltd., a wholly owned subsidiary of Hanmi ( "Hanmi ...
Addition of TUS to VEN+AZA achieves CR/CRh responses in all ( 6/6, 100% ) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh responses in 7/8 ( 88% ) FLT3 wildtype AML, representing 70% of AML population
SAN DIEGO and TORONTO, June 30, 2025 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) APSAPTOF, a clinical-stage precision oncology company developing a tuspetinib ( TUS ) based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia ...
